CHICAGO – In what could change the standard of care for advanced multiple myeloma (MM) patients, providing more hope for an otherwise dire diagnosis, anti-CD38 monoclonal antibody daratumumab reduced the risk of cancer progression by 61 percent and doubled partial and complete response rates just by being added to Velcade (bortezomib, Takeda Oncology Co.) and dexamethasone in a pivotal phase III trial.